LQDA Liquidia Corporation
Legal ·
The 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party.
The deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month.
The complaint alleges Liquidia infringes U.S. Patent No. 11,357,782 and seeks to bar Liquidia from commercializing YUTREPIA if approved. Liquidia says the claims mirror a patent that the Patent Trial and Appeal Board held invalid.
The auditor's report cites recurring losses. Management also changed how it accounts for two amendments to a $100.0 million royalty-backed financing.
A federal judge in Washington denied Liquidia's summary judgment motion on February 27, 2025, upholding the FDA's three-year exclusivity for United Therapeutics' Tyvaso DPI. The exclusivity still ends May 23, 2025, and a related cross claim remains pending.
Liquidia is a biopharmaceutical company focused on respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its revenue comes from YUTREPIA (treprostinil) inhalation powder, which the text says the FDA approved in May 2025 for PAH and PH-ILD, with commercialization beginning in June 2025. YUTREPIA is a dry powder made with the company's proprietary PRINT technology and is delivered with a dry-powder inhaler. The company also shares profit under a promotion agreement with Sandoz for Sandoz's generic treprostinil injection in the United States. Its investigational product L606, a liposomal formulation of treprostinil licensed from Pharmosa Biopharm, is given twice daily with a next-generation nebulizer. L606 is in an open-label study for PAH and PH-ILD in the United States, and the company has initiated a worldwide, placebo-controlled pivotal study for PH-ILD. The company also plans clinical studies of YUTREPIA for pulmonary hypertension associated with COPD, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and Raynaud's phenomenon associated with systemic sclerosis.
| Product or program | What it is | Stage |
|---|---|---|
| YUTREPIA | Inhaled dry powder treprostinil for PAH and PH-ILD | approved |
| L606 | Investigational liposomal treprostinil given twice daily by nebulizer | pivotal study |
| Treprostinil Injection | Generic treprostinil injection sold in the US under a Sandoz promotion agreement |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $158.3 million | $14.0 million |
| Research and development | $39.3 million | $47.8 million |
| Net income (loss) | -$68.9 million | -$128.3 million |
| Cash from operations | -$35.7 million | -$93.4 million |
| Cash and equivalents | $190.7 million | $176.5 million |
Our latest story on this, dated May 8, 2025: "Liquidia files 2024 financials with going-concern doubt, revised debt accounting". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 14, 2026: "Liquidia settles all patent and trade secret litigation with United Therapeutics". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 14, 2026: "Liquidia settles all patent and trade secret litigation with United Therapeutics". The story links the filing or release it is based on. Read the story.
Liquidia Corporation trades under the ticker LQDA on NASDAQ.
Liquidia Corporation is listed on NASDAQ. Our directory also records these other listings: DUS:LT4; FWB:LT4; GETTEX:LT4; HAM:LT4; HAN:LT4; LS:A2JRNS; LSX:A2JRNS; MUN:LT4; SWB:LT4; TRADEGATE:LT4; XETR:LT4.
The SEC Central Index Key (CIK) for Liquidia Corporation is 1819576. Its filings are on SEC EDGAR.
89,508,891 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Liquidia Corporation under United States.
Our directory classifies Liquidia Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Liquidia Corporation is US53635D2027.
aibio.space lists Liquidia Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Liquidia is a biopharmaceutical company focused on respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its revenue comes from YUTREPIA (treprostinil) inhalation powder, which the text says the FDA approved in May 2025 for PAH and PH-ILD, with commercialization beginning in June 2025.
YUTREPIA: Inhaled dry powder treprostinil for PAH and PH-ILD Stage: approved.
L606: Investigational liposomal treprostinil given twice daily by nebulizer Stage: pivotal study.
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,7.01,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio